In This Article:
Zimmer Biomet Holdings, Inc. ZBH recently received the FDA 510(k) clearance for its Persona SoluTion Porous Plasma Spray (“PPS”) Femur. Persona SoluTion PPS Femur is a total knee implant component offering an alternative for patients with sensitivities to bone cement and/or metal.
The latest development is an addition to the company’s clinically proven Persona Knee System. The company expects to commercially launch Persona SoluTion PPS Femur in the United States in the first quarter of 2025.
ZBH’s Likely Stock Trend Following the News
Following the announcement, shares of ZBH moved 0.1% south to $110.62 yesterday.
The company has been gaining a high level of synergies from its expanding Knees business. Per the latest update, Zimmer Biomet is continuously putting efforts into the overall shift of the company’s legacy knee systems to a fully rounded-out Persona portfolio. Henceforth, we expect the latest FDA clearance to motivate market sentiment in favor of ZBH stock in the upcoming days.
ZBH currently has a market capitalization of $22.09 billion. Its earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 1.76%.
About ZBH’s Persona SoluTion PPS Femur
Hypersensitivity to metal is a challenge for patients associated with a traditional cemented total knee replacement (TKR) with an implant made of cobalt-chrome (Co-Cr-Mo) alloy. When exposed to certain metals, people with these hypersensitivities can experience an inflammatory response, pain and implant loosening that may require a revision TKR.
Persona SoluTion PPS Femur combines the company’s latest advances in cementless fixation with decades of proprietary clinical expertise in developing novel materials and surface-hardening processes. It offers cementless fixation with clinically proven PPS coating. Together, they provide initial scratch fit stability and support biological fixation through bony growth.
Persona SoluTion PPS Femur, combined with Persona OsseoTi tibia and Vivacit-E Highly Crosslinked Polyethylene (HXLPE), minimizes the most common metal sensitizers. This is likely to elicit an immune response. The implant is made of Tivanium (Ti-6Al-4V) alloy with more than 17 years of clinical use. The Tivanium alloy is treated with the Ti-Nidium Surface Hardening Process and is compatible with Vivacit-E HXLPE articular surfaces.
Industry Prospects Favor Zimmer Biomet
Per a report by SkyQuest, the global knee replacement market size is expected to reach $16.99 billion by 2031, at a compound annual growth rate of 5.67% during 2024-2031. Key factors responsible for the potential market growth include the rising incidence of osteoarthritis and expanding demand for joint replacement surgeries.